Introduction: Pharmaceutical innovation: Law & the public's health

Journal of Law, Medicine and Ethics

Volumn 37, Issue 2, 2009, Pages 173-175

  Outterson, Kevin ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEVELOPING COUNTRY; DRUG COST; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG SCREENING; ECONOMICS; ETHICS; HEALTH; HEALTH CARE DELIVERY; HUMAN; INTERNATIONAL COOPERATION; LEGAL ASPECT; PATENT; REVIEW; UNITED STATES;

DEVELOPING COUNTRIES; DRUG COSTS; DRUG DISCOVERY; DRUG EVALUATION; DRUG INDUSTRY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERNATIONAL COOPERATION; PATENTS AS TOPIC; UNITED STATES; WORLD HEALTH;

EID: 67650248845     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1111/j.1748-720X.2009.00363.x     Document Type: Review

References (16)

1. IMS Health Lowers 2009 Global Pharmaceutical Market Forecast to 2.5 - 3.5 Percent Growth, Press Release, April 22, 2009, available at http://www.imshealth.com/portal/site/imshealth/menuitem. a46c6d4df3db4b3d88f61109418c22a/?vgnextoid= 1e61fa8adbec0210VgnVCM100000ed152ca2RCRD&vgnextchannel= b5e57900b55a5110VgnVCM10000071812ca2RCRD&vgnextfmt=default (last visited May 6, 2009).
2. See generally K. Outterson Pharmaceutical Arbitrage: Balancing Access and Innovation in International Prescription Drug Markets Yale Journal of Health Policy, Law & Ethics 5, no. 1 (2005 193 291.
3. P. Hunt Human Rights Guidelines for Pharmaceutical Companies in Relation to Access to Medicines draft for consultation, September 19, 2007.
4. J. Bessen and M. J. Meurer, Patent Failure: How Judges, Bureaucrats, and Lawyers Put Innovators at Risk (Princeton : Princeton University Press, 2008).
5. PhRMA, Pharmaceutical Industry Profile (2009).
6. A. S. Kesselheim and J. Avorn Using Patent Data to Assess the Value of Pharmaceutical Innovation Journal of Law, Medicine & Ethics 37, no. 2 (2009 176 183.
7. S. Flynn, A. Hollis, and M. Palmedo An Economic Justification for Open Access to Essential Medicine Patents in Developing Countries Journal of Law, Medicine & Ethics 37, no. 2 (2009 184 208.
8. R. C. Bird Developing Nations and the Compulsory License: Maximizing Access to Essential Medicines While Minimizing Investment Side Effects Journal of Law, Medicine & Ethics 37, no. 2 (2009 209 221.
9. K. M. Lybecker and E. Fowler Compulsory Licensing in Canada and Thailand: Comparing Regimes to Ensure Legitimate Use of the WTO Rules Journal of Law, Medicine & Ethics 37, no. 2 (2009 222 239.
10. J. Sonderholm Wild-Card Patent Extensions as a Means to Incentivize Research and Development of Antibiotics Journal of Law, Medicine & Ethics 37, no. 2 (2009 240 246.
11. J. H. Reichman Comment: A Trilogy of Views about Compulsory Licensing of Patented Pharmaceutical Inventions Journal of Law, Medicine & Ethics 37, no. 2 (2009 247 263.
12. A. Kapczynski Commentary: Innovation Policy for a New Era Journal of Law, Medicine & Ethics 37, no. 2 (2009 264 668.
13. E. W. Leonard Right to Experimental Treatment: FDA New Drug Approval, Constitutional Rights, and the Public's Health Journal of Law, Medicine & Ethics 37, no. 2 (2009 269 279.
14. B. A. Noah Just a Spoonful of Sugar: Drug Safety for Pediatric Populations Journal of Law, Medicine & Ethics 37, no. 2 (2009 280 291.
15. S. E. Crager and M. Price Prizes and Parasites: Incentive Models for Addressing Chagas Disease Journal of Law, Medicine & Ethics 37, no. 2 (2009 292 304.
16. B. Patsner Riegel v. Medtronic, Inc.: Revisiting Pre-emption for Medical Devices Journal of Law, Medicine & Ethics 37, no. 2 (2009 305 317.